Danon disease: further clinical and molecular heterogeneity. - Archive ouverte HAL Access content directly
Journal Articles Muscle & nerve. Supplement. Year : 2009

Danon disease: further clinical and molecular heterogeneity.

(1, 2) , (3) , (4) , (2) , (1, 3) , (1) , (1, 2, 3, 4, 5, 6) , (5) , (3) , (6) , (7) , (1, 2)
1
2
3
4
5
6
7

Abstract

Two families of Greek patients with subclinical to severe cardiomyopathy are presented. The diagnosis of Danon disease was supported by a total lack of LAMP2 immunostaining in cultured skin fibroblasts and muscle biopsies. The LAMP2 mutation carried by one patient (c.928G>A) has already been reported but with different symptoms. The second patient had a novel point deletion. This has not been described previously, but it could be detected easily by restriction analysis. This mutation was also found in the patient's brother, and it was associated with severe cardiomyopathy leading to heart failure. Surprisingly, the proband also had partial reduction of alpha-galactosidase A activity, despite the absence of characteristic clinical features of Fabry disease. A substitution in the GLA gene (c.937G>T) was found, and its involvement in the cardiac disease is discussed.

Dates and versions

inserm-00410415 , version 1 (20-08-2009)

Identifiers

Cite

Frédérique Sabourdy, Helen Michelakakis, Aris Anastasakis, Virginie Garcia, Irene Mavridou, et al.. Danon disease: further clinical and molecular heterogeneity.. Muscle & nerve. Supplement., 2009, 39 (6), pp.837-44. ⟨10.1002/mus.21252⟩. ⟨inserm-00410415⟩
169 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More